Treatment-resistant depression: recent developments and future directions
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
A significant proportion of patients with major depressive disorder (MDD) fail to achieve remission with standard antidepressant therapies, even when optimally delivered. These patients are classified as treatment-resistant depression (TRD), which is distinguished from "difficult-to-treat" depression,1 defined as depression treated under circumstances that precludes the optimal delivery of a potentially beneficial treatment (e.g., subtherapeutic dosing, intolerable side effects, poor adherence, etc.) TRD is also distinguished from severe depression, as some patients with milder depressive symptoms are markedly treatment resistant, whereas others with profound, acute depressive symptoms are quite treatment responsive. Defining the boundaries of TRD is critical from a clinical, research, and public health perspective, as drug and device manufacturers seek new regulatory approvals for numerous indications in the TRD spectrum. This article reviews recent developments in TRD, with a focus on classification methods used for regulatory clinical trials; treatments currently approved in the US for TRD; how classification schemes and regulatory rules have limited understanding of their scope of effectiveness; and what changes are needed in research approaches to facilitate novel therapeutic discovery. There is no validated consensus definition of TRD. At a minimum, TRD signifies depression that has failed to respond to at least one optimally administered therapy. Regulatory authorities such as the European Agency for the Evaluation of Medicinal Products have defined TRD as failure to respond to two products of different classes, used for a sufficient length of time at an adequate dose, without specification of an adequate dose or duration.2 The US FDA does not define TRD. Rather, FDA approved devices or medication describe the specific patient population investigated in pivotal trials demonstrating safety and efficacy. Several rating instruments and classification schemes for treatment resistance have been adopted for use in research studies of TRD, although none are routinely used in clinical settings. At a minimum, these instruments attempt to quantify the number of previous antidepressant trials (including augmentation strategies and electroconvulsive therapy; ECT), assess the adequacy of trials by determining maximum dose and duration, and assess patients' response to treatments.3 Although several instruments have shown reliability and validity in research settings, they have important limitations: (1) Four to six-week monotherapy trials of antidepressants may be categorized as adequate, despite evidence that longer trial durations may be required, particularly for chronic depressions; (2) acceptable antidepressant doses in previous trials include the minimal approved dose, although drugs such as venlafaxine XR may require titration significantly higher than approved doses;4 (3) most critically, the infrequent implementation of measurement-based care5 in clinical practice obstructs the accurate determination of response to previous therapies. Further, the lack of electronic medical records in most treatment settings hinders researchers' ability to obtain records in a timely and efficient manner earlier to study enrollment. Even when obtained, medical records may be difficult to interpret due to incomplete documentation of response, side effects, adherence, and concurrent therapies (psychotherapy, phototherapy, etc.). Salient clinical issues impacting outcome in MDD such as substance use and exercise may be unrecorded. Thus, the validity of TRD may ultimately hinge on the accuracy of patients' self-report of their complex treatment histories and clinical course. Five treatments have received regulatory approval in the US for TRD, including three devices [ECT, vagus nerve stimulation (VNS), transcranial magnetic stimulation (TMS)], one medication (the atypical antipsychotic aripiprazole), and one medicinal food (l-methylfolate). In addition, two industry-supported pivotal trials of deep brain stimulation (DBS) are ongoing, and several pharmacotherapies are expected to seek regulatory approval in the next few years. Although each of these treatments has been studied in patients who meet a broad categorical definition of TRD, the heterogeneity of the specific patient populations and study designs make it difficult to directly compare these therapies. Most recently in October 2008, the Center for Devices and Radiological Health (CDRH) of the FDA approved the NeuroStar TMS system as monotherapy for MDD patients who failed to respond to one earlier antidepressant medication at or above the minimal effective dose and duration in the current episode. In 2007, aripiprazole was approved on the basis of two positive, 6-week placebo-controlled trials in MDD patients who showed an insufficient response to 2–4 courses of an antidepressant medication (of which one trial was conducted prospectively for 8 weeks). VNS was approved
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2003) · The Lancet · doi:10.1016/s0140-6736(03)12705-5 · Cited by 1,706
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033 · cited 2×
“higher than approved doses;([4]) (3) most critically, the infrequent implementation of measurement-based care([5]) in clinical practice obstructs the accurate determination of response to previous therapies.”
BackgroundMethodJohansen-Berg, H., Gutman, D. A., Behrens, T. E. J., Matthews, P. M., Rushworth, M. F. S., Katz, E., Lozano, A. M., & Mayberg, H. S. (2008) · Cerebral Cortex · doi:10.1093/cercor/bhm167 · Cited by 561
Souery, D., Oswald, P., Massat, I., Bailer, U., Bollen, J., Demyttenaere, K., Kasper, S., Lecrubier, Y., Montgomery, S., Serretti, A., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0713 · Cited by 521 · cited 3×
“At a minimum, these instruments attempt to quantify the number of previous antidepressant trials (including augmentation strategies and electroconvulsive therapy; ECT), assess the adequacy of trials by determining maximum dose and duration, and assess patients’ response to treatments.([3]) Although several instruments…”
BackgroundInfluentialSalvadore, G., Cornwell, B. R., Colon-Rosario, V., Coppola, R., Grillon, C., Zarate, C. A., & Manji, H. K. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.014 · Cited by 277 · cited 10×
“The Alzheimer’s Disease Neuroimaging Initiative (ADNI), a public–private partnership funded by NIH, industry, and private foundations, suggests a viable model for biomarker research in TRD.”
InfluentialEffectiveness of electroconvulsive therapy in community settings
Prudic, J., Olfson, M., Marcus, S. C., Fuller, R. B., & Sackeim, H. A. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.09.015 · Cited by 269 · cited 1×
“In this prospective naturalistic study of 347 patients at seven hospitals in the US, remission rates following ECT were found to be substantially lower than in clinical trials, and even among remitters, approximately two-thirds experienced relapse during follow-up.([10]) Registration trials in TRD have generally restr…”
Method
Cited by
Cortico-Basal Ganglia Reward Network: Microcircuitry
Sesack, S. R., & Grace, A. A. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.93 · Cited by 985
“Such a commonality of pathology may have its expression in the increasing convergence of treatment strategies, such as second-generation antipsychotic drugs now being used to treat depression and bipolar disorder (Ketter, 2008; Mathew, 2008).”
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786
“This group of patients can be decribed as suffering from treatment-resistant depression (TRD), nd as a group, they suffer more severe depressive symptoms, xhibit more illness-related disability, and experience a more hronic or relapsing course of illness compared with their nonRD counterparts (8,9).”
Self-citationCognitive dysfunction in depression: Neurocircuitry and new therapeutic strategies
Murrough, J. W., Iacoviello, B., Neumeister, A., Charney, D. S., & Iosifescu, D. V. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.06.006 · Cited by 307
Liu, R.-J., Fuchikami, M., Dwyer, J. M., Lepack, A. E., Duman, R. S., & Aghajanian, G. K. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.128 · Cited by 256
“Currently available antidepressants, which block the reuptake or breakdown of monoamine neurotransmitters, have several serious limitations, including a delay of weeks or months for a therapeutic response with o50% of all patients showing full remission (Berton and Nestler, 2006; Mathew, 2008; Fekadu et al, 2009; Litt…”
BackgroundAccelerated TMS for Depression: A systematic review and meta-analysis
Sonmez, A. I., Camsari, D. D., Nandakumar, A. L., Voort, J. L. V., Kung, S., Lewis, C. P., & Croarkin, P. E. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2018.12.041 · Cited by 255
Metadata
- Authors
- Mathew, S. J.
- Venue
- Depression and Anxiety
- Publisher
- Hindawi Limited
- Published
- 2008-12
- Volume
- 25
- Issue
- 12
- Pages
- 989-992
- ISSN
- 1091-4269 (ISSN-L)
- 1520-6394
- OpenAlex
- W1998997980
- Cited by
- 51
- References
- 6
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.